DOI: 10.36347/SJMCR.2019.v07i12.025

Pages: 811-813

Growth retardation (GR) has various etiologies including the deficit of growth hormone (GH). In this case, the treatment is a replacement by recombinant hormone (rhGH). In some specific situations, such as congenital heart disease associated with GH deficiency, the treatment may appear debatable, because of a risk of repercussions, particularly on the ventricular wall. We received a young patient with severe GR and interventricular and interauricular communications, with a proved GH deficiency. The possibility of treating by rhGH has been discussed. The situation has been reported to cases of patients with Noonan syndrome, which most often associates a GR with indication for rhGH and congenital heart disease. In this context, many studies have established not only the efficacy but especially cardiac safety of this treatment.